胸苷激酶1在不同乳腺癌患者中的表达差异研究★OACSTPCD

Objective To compare the expression of Thymidine Kinase 1 (TK1) in different clinical and pathological types of breast cancer and to explore its clinical significance. Methods In this retrospective study, 96 patients with breast cancer were enrolled. They were divided into different groups according to age, tumor size, pathological grades, lymph node status, ER, PR and HER-2 status. The expres-sions of TK1 in different groups of breast cancer patients were compared. Results The expression of TK1 in breast cancer patients with tumor diameter >2 cm was significantly higher than that in patients with diameter ≤2 cm (P<0.05). The TK1 expression in triple-negative breast cancer patients was also significantly higher than in non-triple negative breast cancer patients (P<0.05). However, there were no significant differences about the expression of TK1 between the patients with different ages, pathological grades, lymph node status, ER, PR, and HER-2 status (P>0.05). Conclusion The TK1 is highly expressed in patients with tumor diameter >2.0 cm and triple-negative breast cancer. It suggests that TK1 is of great significance in the progression of breast cancer and is worthy of further clinical study.